<DOC>
	<DOC>NCT02659059</DOC>
	<brief_summary>The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy. The purpose of part 2 of this study is to compare overall survival of Nivolumab and ipilimumab combined with a short course of chemotherapy to standard of care chemotherapy in first line stage IV NSCLC.</brief_summary>
	<brief_title>Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs. Chemotherapy Alone (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com Men and Women â‰¥ 18 years of age Diagnosed with stage IV NonSmall Cell Lung Cancer Diagnosed with recurrent stage IIIB nonsmall cell lung cancer and failed previous concurrent chemoradiation with no further curative options. Subjects with untreated CNS metastases are excluded. Subjects with carcinomatous meningitis Subjects with an active, known or suspected autoimmune disease. Subjects with a condition requiring systemic treatment with either corticosteroids ( &gt; 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment. Women who are pregnant, plan to become pregnant, and/or breastfeed during the study. Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>